» Articles » PMID: 32773873

Prevalence and Clinical Correlates of Residual Symptoms in Remitted Patients with Bipolar Disorder: An Exploratory Study

Overview
Specialty Psychiatry
Date 2020 Aug 11
PMID 32773873
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This cross-sectional study aimed to evaluate the prevalence and factors associated with residual symptoms (both depressive and manic) in subjects with bipolar disorder (BD).

Materials And Methods: A total of 844 subjects diagnosed BD with an illness of 2 years' duration and minimum of two lifetime episodes and in clinical remission were evaluated for residual symptoms using Hamilton Depression Rating Scale (HAM-D) and Young Mania Rating Scale (YMRS). Based on the severity of residual symptoms, the study groups were divided into four groups.

Results: Sixty-nine percent of the subjects had residual depressive symptoms (i.e., HAM-D score in the range of 1-7) and 59% had residual manic symptoms (i.e., YMRS score in the range of 1-7). The most common residual depressive symptom was psychic anxiety (34%) followed by impaired insight (29%). The most common manic symptom was poor insight (31%) followed by sleep disturbances (25%). Subjects with both sets of residual symptoms had onset of BD at a relatively young age, when compared to those with only residual depressive symptoms. Presence of any comorbid physical illness and substance abuse disorder was significantly higher in those with both sets of residual symptoms.

Conclusions: The present study suggests that a substantial proportion of patients with BD have residual symptoms of both types. Comorbid physical illness and substance use were associated with residual symptoms. Identification and management of residual symptoms are highly essential to improve the overall outcome of patients with BD.

Citing Articles

Residual Fatigue in Unipolar and Bipolar Depression: A Systematic Review.

Pastuszak M, Cubala W, Jakuszkowiak-Wojten K, Kwasny A, Swieczkowski D, Galuszko-Wegielnik M Neuropsychopharmacol Rep. 2025; 45(1):e12519.

PMID: 39783764 PMC: 11713126. DOI: 10.1002/npr2.12519.


Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.

Pastuszak M, Cubala W, Kwasny A Drugs Real World Outcomes. 2024; 11(4):565-571.

PMID: 39269606 PMC: 11589017. DOI: 10.1007/s40801-024-00453-y.


Hippocampal temporal dynamics and spatial heterogeneity unveil vulnerability markers in the offspring of bipolar patients.

Saccaro L, Delavari F, Van De Ville D, Piguet C Bipolar Disord. 2024; 27(1):17-27.

PMID: 39135100 PMC: 11848017. DOI: 10.1111/bdi.13487.


Manic Residual Symptoms Also Deserve Attention: A Symptom Network Analysis of Residual Symptoms in Bipolar Disorder.

Zhao Y, Zhang Y, Zheng S, Fang M, Huang J, Zhang L Neuropsychiatr Dis Treat. 2024; 20:1397-1408.

PMID: 39049936 PMC: 11268721. DOI: 10.2147/NDT.S466090.


"To fast or not to fast?" Ramadan and religiosity through the eyes of people with bipolar disorder: an exploratory study.

Mejri I, Ouali U, Gronholm P, Zgueb Y, Ouertani A, Nacef F Front Psychiatry. 2023; 14:1270000.

PMID: 37908594 PMC: 10613667. DOI: 10.3389/fpsyt.2023.1270000.


References
1.
Gitlin M, Swendsen J, Heller T, Hammen C . Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995; 152(11):1635-40. DOI: 10.1176/ajp.152.11.1635. View

2.
Cretu J, Culver J, Goffin K, Shah S, Ketter T . Sleep, residual mood symptoms, and time to relapse in recovered patients with bipolar disorder. J Affect Disord. 2015; 190:162-166. DOI: 10.1016/j.jad.2015.09.076. View

3.
Malhotra N, Kulhara P, Chakrabarti S, Grover S . A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord. 2013; 150(2):653-8. DOI: 10.1016/j.jad.2013.03.010. View

4.
Benazzi F . Prevalence and clinical correlates of residual depressive symptoms in bipolar II disorder. Psychother Psychosom. 2001; 70(5):232-8. DOI: 10.1159/000056260. View

5.
Freeman M, Stoll A . Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998; 155(1):12-21. DOI: 10.1176/ajp.155.1.12. View